By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market on Thursday a drop in preliminary revenues of almost 1 percent year over year for the third quarter.

The San Diego-based firm said that it estimates revenues for the third quarter to come in at around $235 million, compared to $237.3 million from a year ago. That figure also is well below the Wall Street consensus estimate of $277.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.